SANTA CLARA, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today released its 2022 ESG Report highlighting accomplishments in environmental, social, and governance (ESG) across its global markets.

“We are proud to release our ESG Report, which showcases our continued progress during 2022 towards developing a more sustainable business across our global business and to being a responsible corporate citizen that prioritizes our ethical values, inclusive culture and environmental initiatives,” said Doug Godshall, President and Chief Executive Officer, “The Corporate Values that drive us at Shockwave go beyond our patient-centric devices and extend to addressing the impact that our company has on the those with whom we interact, including our employees, customers, suppliers, communities and stockholders. We know our ESG efforts will continue to evolve as our business and the world change, and we are committed to learning throughout this journey and finding ways to make as much positive impact as possible.”

Throughout 2022, Shockwave took several important actions to advance its ESG program, which is focused on five grounding principles: Planet, People, Products, Community and Governance. The report highlights our ESG accomplishments, including:

• Measuring our greenhouse gas emissions for 2022
• Adding new electric vehicle charging stations to our Santa Clara buildings
• Pursuing LEED and Fitwel certifications for our future Costa Rica manufacturing site
• Continuing to grow of our all-women Shockwave Women Achieving Together, dedicated to advancing the careers of women in engineering, technology and cardiovascular devices
• Making significant progress toward ISO 14001 certification, which is on target for completion in 2023
  
  

Shockwave Medical’s annual ESG Report can be found on the company’s investor relations site at the following link: Shockwave 2022 ESG Report. All data in the report reflects fiscal year 2022, unless noted otherwise.

About Shockwave Medical, Inc.
Shockwave Medical is a leader in the development and commercialization of innovative products that are transforming the treatment of cardiovascular disease. Its first-of-its-kind Intravascular Lithotripsy (IVL) technology has transformed the treatment of atherosclerotic cardiovascular disease by safely using sonic pressure waves to disrupt challenging calcified plaque, resulting in significantly improved patient outcomes. Shockwave has also recently acquired the Neovasc Reducer, which is under clinical investigation in the United States and is CE Marked in the European Union and the United Kingdom. By redistributing blood flow within the heart, the Reducer is designed to provide relief to the millions of patients worldwide suffering from refractory angina. Learn more at www.shockwavemedical.com and www.neovasc.com.

Forward-Looking Statements
This press release contains statements relating to our expectations, activities, programs, goals, events or developments that we expect, believe or anticipate will or may occur, which are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, are statements that could be deemed forward-looking. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” and similar expressions, and the negative of these terms. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current plans, expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which we are not currently aware.

Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others: risks and uncertainties related to market conditions. These factors, as well as others, are discussed in our filings with the Securities and Exchange Commission (SEC), including in Part I, Item IA - Risk Factors in our most recent Annual Report on Form 10-K filed with the SEC, and in our other periodic and other reports filed with the SEC. Except to the extent required by law, we do not undertake to update any of these forward-looking statements after the date hereof to conform these statements to actual results or revised expectations.

Media Contact:
Scott Shadiow
+1.317.432.9210
sshadiow@shockwavemedical.com

Investor Contact:
Debbie Kaster
dkaster@shockwavemedical.com